Is high-risk neuroblastoma induction chemotherapy possible without G-CSF? A pilot study of safety and treatment delays in the absence of primary prophylactic hematopoietic growth factors.
Sarah B WhittleValeria SmithAllison SilversteinMargaret ParmeterCharles G MinardMelanie Brooke BernhardtPeter E ZageRajkumar VenkatramaniJed G NuchternAndras HeczeyHeidi V RussellJason M ShohetJennifer H FosterPublished in: Pediatric blood & cancer (2020)
A greater than expected number of serious bacterial infections were observed during administration of induction chemotherapy for HR-NBL without primary prophylactic G-CSF. These results support continued prophylactic administration growth factor during induction chemotherapy.